IRIS
SALPINI, ROMINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.311
EU - Europa 1.847
AS - Asia 945
OC - Oceania 86
SA - Sud America 23
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 9
Totale 20.230
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.298
SG - Singapore 581
IT - Italia 439
IE - Irlanda 258
DE - Germania 216
UA - Ucraina 193
CN - Cina 190
FR - Francia 167
PL - Polonia 159
SE - Svezia 143
KR - Corea 103
AU - Australia 80
GB - Regno Unito 70
FI - Finlandia 68
RU - Federazione Russa 51
CZ - Repubblica Ceca 33
BE - Belgio 21
VN - Vietnam 19
JP - Giappone 15
CA - Canada 13
IN - India 11
ES - Italia 9
BR - Brasile 7
CO - Colombia 6
HK - Hong Kong 6
NZ - Nuova Zelanda 6
BG - Bulgaria 5
CM - Camerun 5
EU - Europa 5
NL - Olanda 5
RO - Romania 5
TR - Turchia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AR - Argentina 4
CH - Svizzera 4
CL - Cile 4
IQ - Iraq 4
KG - Kirghizistan 2
MN - Mongolia 2
NG - Nigeria 2
AM - Armenia 1
BD - Bangladesh 1
DK - Danimarca 1
EC - Ecuador 1
IR - Iran 1
LK - Sri Lanka 1
NP - Nepal 1
PE - Perù 1
SA - Arabia Saudita 1
TW - Taiwan 1
ZA - Sudafrica 1
ZW - Zimbabwe 1
Totale 20.230
Salva come PNG Salva come JPEG
Città #
Wilmington 4.628
Woodbridge 4.352
Houston 3.871
Fairfield 753
Chandler 512
Singapore 505
Ann Arbor 396
Ashburn 285
Seattle 273
Cambridge 245
Dublin 207
Rome 173
New York 163
Jacksonville 160
Kraków 157
Medford 140
Santa Clara 134
Dearborn 101
Beijing 93
Lawrence 67
Milan 66
San Diego 55
Menlo Park 39
Moscow 32
Melbourne 29
Zhengzhou 29
Sydney 28
Helsinki 27
La Veta 27
Mülheim 27
Munich 25
Palo Alto 23
Creede 21
Brussels 20
Cedarhurst 20
Brno 19
Canberra 19
Washington 17
Engelhard 16
Redwood City 16
London 15
Colorado Springs 14
Council Bluffs 14
Falls Church 14
Naples 14
Olomouc 14
San Francisco 14
Seoul 13
Boardman 11
San Jose 10
Verona 10
Nanjing 9
Nuremberg 9
Toronto 9
Genoa 8
Nanchang 8
Norwalk 8
Phoenix 8
Shanghai 8
St. George 8
Tokyo 8
Dong Ket 7
Guangzhou 7
Kilburn 7
Padova 7
University Park 7
Auckland 6
Bari 6
Hanoi 6
Hefei 6
Hong Kong 6
Los Angeles 6
Mountain View 6
Albano Laziale 5
Fort Worth 5
Ho Chi Minh City 5
Hounslow 5
Garbagnate Milanese 4
Hanover 4
North Hollywood 4
Roebling 4
Saint Petersburg 4
São Paulo 4
Amsterdam 3
Baghdad 3
Bogotá 3
Buenos Aires 3
Buzau 3
Campinas 3
Evanston 3
Istanbul 3
Jinan 3
Lappeenranta 3
Manitou Springs 3
Perugia 3
Redmond 3
Wuhan 3
Yaoundé 3
Alcalá de Henares 2
Atlanta 2
Totale 18.166
Salva come PNG Salva come JPEG
Nome #
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 494
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 452
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 443
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 433
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 432
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 432
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 427
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 426
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 419
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 411
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 408
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 400
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 399
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 397
Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal 396
Molecular analysis of hepatitis B virus in Bulgaria 394
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 387
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 383
Molecular Epidemiology of HIV Type 1 CRF02_AG in Cameroon and African Patients Living in Italy 382
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 378
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 378
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B 375
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. 371
HBV, HCV, HDV AND HEV COINFECTIONS IN A COHORT OF HIV POSITIVE PATIENTS IN CAMEROON 371
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 371
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 368
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 367
Combined analysis of the prevalence of drug-resistant Hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE) 363
When phylogenetic analysis complements the epidemiological investigation: a case of HIV-2 infection, Italy 362
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 358
HIV-2 A-subtype gp125(C2-V3-C3) mutations and their association with CCR5 and CXCR4 tropism. 357
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 357
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 355
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 339
Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon 336
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 336
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy 334
High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance 326
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 321
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. 316
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 309
HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets 286
HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy 238
Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis 234
Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: A case report 225
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe 218
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy 199
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection 173
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 169
Different patterns of HIV-1 replication in MACROPHAGES is led by co-receptor usage 162
Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir 157
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: Evidence from routine clinical practice in Cameroon 144
Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS® Ampliprep/COBAS®TaqMan HBV test v2.0 135
Reliable timescale inference of HBV genotype A origin and phylodynamics 129
Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation 117
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 109
Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis 108
In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy. 102
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses 93
New markers in monitoring the reactivation of hepatitis B virus infection in immunocompromised hosts 91
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 90
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 89
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 82
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 74
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control 70
Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers 67
Virological reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir-sparing therapy as revealed by highly-sensitive HBV assays. 63
HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation 62
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 57
for the Icona Foundation Study Group Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays. 56
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 55
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 49
Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B 46
HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA After Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort 45
SARS-CoV-2 variants and their relevant mutational profiles: update summer 2021 45
An increase in the levels of middle surface antigen characterizes patients developing HBV-driven liver cancer despite prolonged virological suppression 41
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile 36
Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis 35
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses 34
Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort 33
Circulation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencing. 33
Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: An extensive analysis of HBV genome. 31
HBcrAg tightly correlates with elevated HDV replicative activity and with enhanced liver inflammation and damage: role of HBcrAg as a biomarker of liver disease progression in the setting of HDV co-infection 31
A high genetic heterogeneity in HBsAg can affect immunogenicity in acute hepatitis B infection. 30
Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach 29
Editorial: The current challenges underlying hepatitis D virus infection 28
Crucial Role of Central Nervous System as a Viral Anatomical Compartment for HIV-1 Infection 27
Acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg stability and secretion and promotes cell survival 27
Hepatitis B-related hepatic flare during immune reconstitution syndrome after antiretroviral treatment initiation in an HBV surface antigen-positive patient with HIV: viroimmunological and histological characterization 24
Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the early phases of chronic infection even in the setting of limited liver damage 24
HIV DNA viral reservoirs in blood and gut-associated lymphoid tissues (GALT): Implications of switch from triple antiretroviral therapy (ART) to 2-drug dolutegravir/lamivudine regimens 24
Hepatitis delta virus (HDV) infection : frequency and outcome in persons living with HIV (PLWH). Data from the ICONA (Italian cohort of naïve for antiretrovirals) cohort 24
The acquisition of positively charged amino acids in HBsAg C- terminus impairs HBsAg secretion, affects its structural stability and is associated with HBV-induced liver cancer 24
Ultrasensitive HBV-RNA quantification by droplet digital PCR is a promising biomarker to optimize the staging of chronic HBV infection and to identify minimal viral activity under prolonged virological suppression. 23
HDV epidemic in Central Italy is stable over the last two decades and is characterized by the circulation of multiple HDV subgenotypes 1 inducing different inflammatory stimuli 23
Transcriptionally active HBV integrations frequently occur in the early phases of chronic infection and mostly involve genetic regions crucial for cell proliferation. 23
THE ENRICHMENT OF POSITIVELY CHARGED AMINO ACIDS IN HBsAg C-TERMINUS IMPAIRS HBsAg SECRETION, AFFECTS ITS STRUCTURAL STABILITY AND IS CORRELATED WITH HBV-INDUCED LIVER CANCER. 22
The transactivation of endogenous retroviruses correlates with HIV reservoir, lymphocytes activation and low CD4 count in virologically suppressed patients 21
An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein. 21
Kinetics of HBsAg forms in chronic hepatitis delta patients treated with bulevirtide for 48 weeks: correlation with virological response 20
Totale 20.390
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.443
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.443
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.079 0 0 0 462 430 630 467 429 483 458 356 364
2020/20213.266 336 360 329 387 317 390 491 326 66 108 112 44
2021/20221.052 58 66 47 49 38 86 58 48 305 53 28 216
2022/20231.356 125 128 105 149 133 244 92 122 111 21 100 26
2023/2024935 165 26 99 52 92 155 44 17 57 83 21 124
2024/20251.047 112 600 315 20 0 0 0 0 0 0 0 0
Totale 20.634